Pathogenesis of Lupus Nephritis

Systemic Lupus Erythematosus

Volumn , Issue , 2011, Pages 453-473

  Du, Yong ^a   Mohan, Chandra ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84866882257     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374994-9.10026-9     Document Type: Chapter

References (293)

1. Kanta H., Mohan C. Three checkpoints in lupus development: central tolerance in adaptive immunity, peripheral amplification by innate immunity and end-organ inflammation. Genes Immun 2009, 10(5):390-396.
2. Andrews B.S., Eisenberg R.A., Theofilopoulos A.N., Izui S., Wilson C.B., McConahey P.J., et al. Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J Exp Med 1978, 148(5):1198-1215.
3. Theofilopoulos A.N., Dixon F.J. Murine models of systemic lupus erythematosus. Adv Immunol 1985, 37:269-390.
4. Fairhurst A.M., Wandstrat A.E., Wakeland E.K. Systemic lupus erythematosus: multiple immunological phenotypes in a complex genetic disease. Adv Immunol 2006, 92:1-69.
5. Rudofsky U.H., Evans B.D., Balaban S.L., Mottironi V.D., Gabrielsen A.E. Differences in expression of lupus nephritis in New Zealand mixed H-2z homozygous inbred strains of mice derived from New Zealand black and New Zealand white mice. Origins and initial characterization. Lab Invest 1993, 68(4):419-426.
6. Santiago-Raber M.L., Laporte C., Reininger L., Izui S. Genetic basis of murine lupus. Autoimmun Rev 2004, 3(1):33-39.
7. Pisitkun P., Deane J.A., Difilippantonio M.J., Tarasenko T., Satterthwaite A.B., Bolland S. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 2006, 312(5780):1669-1672.
8. Subramanian S., Tus K., Li Q.Z., Wang A., Tian X.H., Zhou J., et al. A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc Natl Acad Sci USA 2006, 103(26):9970-9975.
9. Deane J.A., Pisitkun P., Barrett R.S., Feigenbaum L., Town T., Ward J.M., et al. Control of Toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation. Immunity 2007, 27(5):801-810.
10. Santiago-Raber M.L., Kikuchi S., Borel P., Uematsu S., Akira S., Kotzin B.L., et al. Evidence for genes in addition to Tlr7 in the Yaa translocation linked with cceleration of systemic lupus erythematosus. J Immunol 2008, 181(2):1556-1562.
11. Nagata S., Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol Today 1996, 16(1):39-43.
12. Pusey C.D. Anti-glomerular basement membrane disease. Kidney Int 2006, 64(4):1535-1550.
13. Butkowski R.J., Langeveld J.P., Wieslander J., Hamilton J., Hudson B.G. Localization of the Goodpasture epitope to a novel chain of basement membrane collagen. J Biol Chem 1987, 262(16):7874-7877.
14. Saus J., Wieslander J., Langeveld J.P., Quinones S., Hudson B.G. Identification of the Goodpasture antigen as the alpha 3(IV) chain of collagen IV. J Biol Chem 1998, 263(26):13374-13380.
15. Fu Y., Du Y., Mohan C. Experimental anti-GBM disease as a tool for studying spontaneous lupus nephritis. Clin Immunol 2007, 124(2):109-118.
16. Ceppellini R., Polli E., Celada F. A DNA-reacting factor in serum of a patient with lupus erythematosus diffusus. Proc Soc Exp Biol Med 1957, 96(3):572-574.
17. Koren E., Koscec M., Wolfson-Reichlin M., Ebling F.M., Tsao B., Hahn B.H., et al. Murine and human antibodies to native DNA that cross-react with the A and D SnRNP polypeptides cause direct injury of cultured kidney cells. J Immunol 1995, 154(9):4857-4864.
18. Ehrenstein M.R., Katz D.R., Griffiths M.H., Griffiths M.H., Papadaki L., Winkler T.H., et al. Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. Kidney Int 1995, 48(3):705-711.
19. Mason L.J., Ravirajan C.T., Latchman D.S., Isenberg D.A. A human anti-dsDNA monoclonal antibody caused hyaline thrombi formation in kidneys of 'leaky' SCID mice. Clin Exp Immunol 2001, 126(1):137-142.
20. Liang Z., Xie C., Chen C., Kreska D., Hsu K., Li L., et al. Pathogenic profiles and molecular signatures of antinuclear autoantibodies rescued from NZM2410 lupus mice. J Exp Med 2004, 199(3):381-398.
21. Tsao B.P., Ohnishi K., Cheroutre H., Mitchell B., Teitell M., Mixter P., et al. Failed self-tolerance and autoimmunity in IgG anti-DNA transgenic mice. J Immunol 1992, 149(1):350-358.
22. Fenton K.A., Rekvig O.P. A central role of nucleosomes in lupus nephritis. Ann N Y Acad Sci 2007, 1108:104-113.
23. Yung S., Chan T.M. Anti-DNA antibodies in the pathogenesis of lupus nephritis- The emerging mechanisms. Autoimmun Rev 2008, 7(4):317-321.
24. Mortensen E.S., Rekvig O.P. Nephritogenic potential of anti-DNA antibodies against necrotic nucleosomes. J Am Soc Nephrol 2009, 20(4):696-704.
25. Clynes R., Dumitru C., Ravetch J.V. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 1998, 279(5353):1052-1054.
26. Watanabe H., Sherris D., Gilkeson G.S. Soluble CD16 in the treatment of murine lupus nephritis. Clin Immunol Immunopathol 1998, 88(1):91-95.
27. Werwitzke S., Trick D., Sondermann P., Kamino K., Schlegelberger B., Kniesch K., et al. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32). Ann Rheum Dis 2008, 67(2):154-161.
28. Bao L., Zhou J., Holers V.M., Quigg R.J. Excessive matrix accumulation in the kidneys of MRL/lpr lupus mice is dependent on complement activation. J Am Soc Nephrol 2003, 14(10):2516-2525.
29. Bao L., Haas M., Boackle S.A., Kraus D.M., Cunningham P.N., Park P., et al. Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice. J Immunol 2002, 168(7):3601-3607.
30. Robson M.G., Cook H.T., Botto M., Taylor P.R., Busso N., Salvi R., et al. Accelerated nephrotoxic nephritis is exacerbated in C1q-deficient mice. J Immunol 2001, 166(11):6820-6828.
31. Hébert M.J., Takano T., Papayianni A., Rennke H.G., Minto A., Salant D.J., et al. Acute nephrotoxic serum nephritis in complement knockout mice: relative roles of the classical and alternate pathways in neutrophil recruitment and proteinuria. Nephrol Dial Transplant 1998, 13(11):2799-2803.
32. Qing X., Zavadil J., Crosby M.B., Hogarth M.P., Hahn B.H., Mohan C., et al. Nephritogenic anti-DNA antibodies regulate gene expression in MRL/lpr mouse glomerular mesangial cells. Arthritis Rheum 2006, 54(7):2198-2210.
33. Deshmukh U.S., Bagavant H., Fu S.M. Role of anti-DNA antibodies in the pathogenesis of lupus nephritis. Autoimmun Rev 2006, 5(6):414-418.
34. Radic M.Z., Weigert M. Genetic and structural evidence for antigen selection of anti-DNA antibodies. Annu Rev Immunol 1994, 12:487-520.
35. Katz J.B., Limpanasithikul W., Diamond B. Mutational analysis of an autoantibody: differential binding and pathogenicity. J Exp Med 1994, 180(3):925-932.
36. Limaye N., Mohan C. Pathogenicity of anti-DNA and anti-glomerular antibodies: weighing the evidence. Drug Discovery Today: Disease Models 2004, 1(4):395-403.
37. Fu Y., Xie C., Chen J., Zhu J., Zhou H., Thomas J., Mohan C., et al. Innate stimuli accentuate end-organ damage by nephrotoxic antibodies via Fc receptor and TLR stimulation and IL-1/TNF-alpha production. J Immunol 2006, 176(1):632-639.
38. Boes M., Schmidt T., Linkemann K., Beaudette B.C., Marshak-Rothstein A., Chen J. Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc Natl Acad Sci USA 2000, 97(3):1184-1189.
39. Werwitzke S., Trick D., Kamino K., Matthias T., Kniesch K., Schlegelberger B., et al. Inhibition of lupus disease by anti-double-stranded DNA antibodies of the IgM isotype in the (NZB x NZW) F1 mouse. Arthritis Rheum 2005, 52(11):3629-3638.
40. Forger F., Matthias T., Oppermann M., Becker H., Helmke K. Clinical significance of anti-dsDNA antibody isotypes: IgG/IgM ratio of anti-dsDNA antibodies as a prognostic marker for lupus nephritis. Lupus 2004, 13(1):36-44.
41. Li Q.Z., Xie C., Wu T., Mackay M., Aranow C., Putterman C., et al. Identification of autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays. J Clin Invest 2005, 115(12):3428-3439.
42. Alba P., Bento L., Cuadrado M.J., Karim Y., Tungekar M.F., Abbs I., et al. Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis. Ann Rheum Dis 2003, 62(6):556-560.
43. Gladman D.D., Urowitz M.B., Keystone E.C. Serologically active clinically quiescent systemic lupus erythematosus: a discordance between clinical and serologic features. Am J Med 1979, 66(2):210-215.
44. Gladman D.D., Hirani N., Ibañez D., Urowitz M.B. Clinically active serologically quiescent systemic lupus erythematosus. J Rheumatol 2003, 30(9):1960-1962.
45. Kong P.L., Zhu T., Madaio M.P., Craft J. Role of the H-2 haplotype in Fas-intact lupus-prone MRL mice: association with autoantibodies but not renal disease. Arthritis Rheum 2003, 48(10):2992-2995.
46. Singh R.R., Saxena V., Zang S., Li L., Finkelman F.D., Witte D.P., et al. Differential contribution of IL-4 and STAT6 vs. STAT4 to the development of lupus nephritis. J Immunol 2003, 170(9):4818-4825.
47. Jacob C.O., Zang S., Li L., Ciobanu V., Quismorio F., Mizutani A., et al. Pivotal role of Stat4 and Stat6 in the pathogenesis of the lupus-like disease in the New Zealand mixed 2328 mice. J Immunol 2003, 171(3):1564-1571.
48. Waters S.T., McDuffie M., Bagavant H., Deshmukh U.S., Gaskin F., Jiang C., et al. Breaking tolerance to double stranded DNA, nucleosome, and other nuclear antigens is not required for the pathogenesis of lupus glomerulonephritis. J Exp Med 2004, 199(2):255-264.
49. Stohl W., Xu D., Kim K.S., Koss M.N., Jorgensen T.N., Deocharan B., et al. BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum 2005, 52(7):2080-2091.
50. Shi X., Xie C., Chang S., Zhou X.J., Tedder T., Mohan C. CD19 hyperexpression augments Sle1-induced humoral autoimmunity but not clinical nephritis. Arthritis Rheum 2007, 56(9):3057-3069.
51. Waters S.T., Fu S.M., Gaskin F., Deshmukh U.S., Sung S.S., Kannapell C.C., et al. NZM2328: a new mouse model of systemic lupus erythematosus with unique genetic susceptibility loci. Clin Immunol 2001, 100(3):372-383.
52. Christensen S.R., Kashgarian M., Alexopoulou L., Flavell R.A., Akira S., Shlomchik M.J. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med 2005, 202(2):321-331.
53. Chan O.T., Hannum L.G., Haberman A.M., Madaio M.P., Shlomchik M.J. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 1999, 189(10):1639-1648.
54. Rumore P.M., Steinman C.R. Endogenous circulating DNA in systemic lupus erythematosus. Occurrence as multimeric complexes bound to histone. J Clin Invest 1990, 86(1):69-74.
55. Decker P. Nucleosome autoantibodies. Clin Chim Acta 2006, 366(1-2):48-60.
56. Burlingame R.W., Boey M.L., Starkebaum G., Rubin R.L. The central role of chromatin in autoimmune responses to histones and DNA in systemic lupus erythematosus. J Clin Invest 1994, 94(1):184-192.
57. Amoura Z., Chabre H., Koutouzov S., Lotton C., Cabrespines A., Bach J.F., et al. Nucleosome-restricted antibodies are detected before anti-dsDNA and/or antihistone antibodies in serum of MRL-Mp lpr/lpr and +/+ mice, and are present in kidney eluates of lupus mice with proteinuria. Arthritis Rheum 1994, 37(11):1684-1688.
58. Voynova E.N., Tchorbanov A.I., Todorov T.A., Vassilev T.L. Breaking of tolerance to native DNA in nonautoimmune mice by immunization with natural protein/DNA complexes. Lupus 2005, 14(7):543-550.
59. Mohan C., Adams S., Stanik V., Datta S.K. Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus. J Exp Med 1993, 177(5):1367-13681.
60. - T helper cell lines augment the production of idiotypes shared by pathogenic anti-DNA autoantibodies in the NZB x SWR model of lupus nephritis. J Immunol 1998, 140(7):2215-2224.
61. Adams S., Leblanc P., Datta S.K. Junctional region sequences of T-cell receptor beta-chain genes expressed by pathogenic anti-DNA autoantibody-inducing helper T cells from lupus mice: possible selection by cationic autoantigens. Proc Natl Acad Sci USA 1991, 88(24):11271-11275.
62. Rajagopalan S., Zordan T., Tsokos G.C., Datta S.K. Pathogenic anti-DNA autoantibody-inducing T helper cell lines from patients with active lupus nephritis: isolation of CD4-8- T helper cell lines that express the gamma delta T-cell antigen receptor. Proc Natl Acad Sci USA 1990, 87(18):7020-7024.
63. Mevorach D., Zhou J.L., Song X., Elkon K.B. Systemic exposure to irradiated apoptotic cells induces autoantibody production. J Exp Med 1998, 188(2):387-392.
64. Munoz L.E., van Bavel C., Franz S., Berden J., Herrmann M., van der Vlag J. Apoptosis in the pathogenesis of systemic lupus erythematosus. Lupus 2008, 17(5):371-375.
65. Cohen P.L. Apoptotic cell death and lupus. Springer Semin Immunopathol 2006, 28(2):145-152.
66. van Bruggen M.C., Kramers C., Hylkema M.N., Smeenk R.J., Berden J.H. Significance of anti-nuclear and anti-extracellular matrix autoantibodies for albuminuria in murine lupus nephritis; a longitudinal study on plasma and glomerular eluates in MRL/l mice. Clin Exp Immunol 1996, 105(1):132-139.
67. Elouaai F., Lulé J., Benoist H., Appolinaire-Pilipenko S., Atanassov C., Muller S., et al. Autoimmunity to histones, ubiquitin, and ubiquitinated histone H2A in NZB x NZW and MRL-lpr/lpr mice. Anti-histone antibodies are concentrated in glomerular eluates of lupus mice. Nephrol Dial Transplant 1994, 9(4):362-366.
68. Xie C., Liang Z., Chang S., Mohan C. Use of a novel elution regimen reveals the dominance of polyreactive antinuclear autoantibodies in lupus kidneys. Arthritis Rheum 2003, 48(8):2343-2352.
69. Krishnan C., Kaplan M.H. Immunopathologic studies of systemic lupus erythematosus. II. Antinuclear reaction of gamma-globulin eluted from homogenates and isolated glomeruli of kidneys from patients with lupus nephritis. J Clin Invest 1967, 46(4):569-579.
70. Jovelin F., Mostoslavsky G., Amoura Z., Chabre H., Gilbert D., Eilat D., et al. Early anti-nucleosome autoantibodies from a single MRL+/+ mouse: fine specificity, V gene structure and pathogenicity. Eur J Immunol 1998, 28(11):3411-3422.
71. Coritsidis G.N., Lombardo F., Rumore P., Kuo S.F., Izzo R., Mir R., et al. Nucleosome effects on mesangial cell matrix and proliferation: a possible role in early lupus nephritis. Exp Nephrol 2002, 10(3):216-226.
72. Shlomchik M.J., Madaio M.P. The role of antibodies and B cells in the pathogenesis of lupus nephritis. Springer Semin Immunopathol 2003, 24(4):363-375.
73. Clatworthy M.R., Smith K.G. B cells in glomerulonephritis: focus on lupus nephritis. Semin Immunopathol 2007, 29(4):337-353.
74. Shlomchik M.J. Sites and stages of autoreactive B cell activation and regulation. Immunity 2008, 28(1):18-28.
75. Hibbs M.L., Tarlinton D.M., Armes J., Grail D., Hodgson G., Maglitto R., et al. Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell 1995, 83(2):301-311.
76. Li D.H., Winslow M.M., Cao T.M., Chen A.H., Davis C.R., Mellins E.D., et al. Modulation of peripheral B cell tolerance by CD72 in a murine model. Arthritis Rheum 2008, 58(10):3192-3204.
77. Nishimura H., Nose M., Hiai H., Minato N., Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999, 11(2):141-151.
78. Kumar K.R., Li L., Yan M., Bhaskarabhatla M., Mobley A.B., Nguyen C., et al. Regulation of B cell tolerance by the lupus susceptibility gene Ly108. Science 2006, 312(5780):1665-1669.
79. Wandstrat A.E., Nguyen C., Limaye N., Chan A.Y., Subramanian S., Tian X.H., et al. Association of extensive polymorphisms in the SLAM/CD2 gene cluster with murine lupus. Immunity 2004, 21(6):769-780.
80. Chan O., Shlomchik M.J. A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr/lpr mice. J Immunol 1998, 160(1):51-59.
81. Pierce S.K., Morris J.F., Grusby M.J., Kaumaya P., van Buskirk A., Srinivasan M., et al. Antigen-presenting function of B lymphocytes. Immunol Rev 1988, 106:149-180.
82. Liang B., Gardner D.B., Griswold D.E., Bugelski P.J., Song X.Y. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology 2006, 119(3):296-305.
83. Ishida H. Clinical implication of IL-10 in patients with immune and inflammatory diseases. Rinsho Byori 1994, 42(8):843-852.
84. Harris D.P., Haynes L., Sayles P.C., Duso D.K., Eaton S.M., Lepak N.M., et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 2000, 1(6):475-482.
85. Bhat P., Radhakrishnan J. B lymphocytes and lupus nephritis: new insights into pathogenesis and targeted therapies. Kidney Int 2008, 73(3):261-268.
86. Jabs D.A., Burek C.L., Hu Q., Kuppers R.C., Lee B., Prendergast R.A. Anti-CD4 monoclonal antibody therapy suppresses autoimmune disease in MRL/Mp-lpr/lpr mice. Cell Immunol 1992, 141(2):496-507.
87. D'Agati V.D., Appel G.B., Estes D., Knowles D.M., Pirani C.L. Monoclonal antibody identification of infiltrating mononuclear leukocytes in lupus nephritis. Kidney Int 1986, 30(4):573-581.
88. Díaz Gallo C., Jevnikar A.M., Brennan D.C., Florquin S., Pacheco-Silva A., Kelley V.R. Autoreactive kidney-infiltrating T-cell clones in murine lupus nephritis. Kidney Int 1992, 42(4):851-859.
89. Giese T., Davidson W.F. Evidence for early onset, polyclonal activation of T cell subsets in mice homozygous for lpr. J Immunol 1992, 149(9):3097-3106.
90. Mukherjee R., Zhang Z., Zhong R., Yin Z.Q., Roopenian D.C., Jevnikar A.M. Lupus nephritis in the absence of renal major histocompatibility complex class I and class II molecules. J Am Soc Nephrol 1996, 7(11):2445-2452.
91. Koh D.R., Ho A., Rahemtulla A., Fung-Leung W.P., Griesser H., Mak T.W. Murine lupus in MRL/lpr mice lacking CD4 or CD8 T cells. Eur J Immunol 1995, 25(9):2558-2562.
92. Chesnutt M.S., Finck B.K., Killeen N., Connolly M.K., Goodman H., Wofsy D. Enhanced lymphoproliferation and diminished autoimmunity in CD4-deficient MRL/lpr mice. Clin Immunol Immunopathol 1998, 87(1):23-32.
93. Jabs D.A., Kuppers R.C., Saboori A.M., Burek C.L., Enger C., Lee B., et al. Effects of early and late treatment with anti-CD4 monoclonal antibody on autoimmune disease in MRL/MP-lpr/lpr mice. Cell Immunol 1994, 154(1):66-76.
94. Mohan C., Shi Y., Laman J.D., Datta S.K. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 1995, 154(3):1470-1480.
95. + T cells recognizing specific antigen deposited in glomeruli cause glomerulonephritis-like kidney injury. Clin Immunol 2002, 104(2):161-173.
96. Lou Y.H. Anti-GBM glomerulonephritis: a T cell-mediated autoimmune disease?. Arch Immunol Ther Exp (Warsz) 2004, 52(2):96-103.
97. Desai-Mehta A., Lu L., Ramsey-Goldman R., Datta S.K. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996, 97(9):2063-2073.
98. Koshy M., Berge D., Crow M.K. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 1996, 98(3):826-837.
99. Devi B.S., Van Noordin S., Krausz T., Davies K.A. Peripheral blood lymphocytes in SLE-hyperexpression of CD154 on T and B lymphocytes and increased number of double negative T cells. J Autoimmun 1998, 11(5):471-475.
100. Datta S.K. Major peptide autoepitopes for nucleosome-centered T and B cell interaction in human and murine lupus. Ann N Y Acad Sci 2003, 987:79-90.
101. Yi Y., McNerney M., Datta S.K. Regulatory defects in Cbl and mitogen-activated protein kinase (extracellular signal-related kinase) pathways cause persistent hyperexpression of CD40 ligand in human lupus T cells. J Immunol 2001, 165(11):6627-6634.
102. Mehling A., Loser K., Varga G., Metze D., Luger T.A., Schwarz T., et al. Overexpression of CD40 ligand in murine epidermis results in chronic skin inflammation and systemic autoimmunity. J Exp Med 2001, 194(5):615-628.
103. Kalled S.L., Cutler A.H., Datta S.K., Thomas D.W. Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function. J Immunol 1998, 160(5):2158-2165.
104. Wang X., Huang W., Schiffer L.E., Mihara M., Akkerman A., Hiromatsu K., et al. Effects of anti-CD154 treatment on B cells in murine systemic lupus erythematosus. Arthritis Rheum 2003, 48(2):495-506.
105. Early G.S., Zhao W., Burns C.M. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand Black x New Zealand White mice. Response correlates with the absence of an anti-antibody response. J Immunol 1996, 157(7):3159-3164.
106. Grewal I.S., Xu J., Flavell R.A. Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature 1995, 378(6557):617-620.
107. Wu Y., Xu J., Shinde S., Grewal I.S., Henderson T., Flavell R.A., et al. Rapid induction of a novel costimulatory activity on B cells by CD40 ligand. Curr Biol 1995, 5(11):1303-1311.
108. Schönbeck U., Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001, 58(1):4-43.
109. Crow M.K. Modification of accessory molecule signaling. Springer Semin Immunopathol 2006, 27(4):409-424.
110. Alderson M.R., Armitage R.J., Tough T.W., Strockbine L., Fanslow W.C., Spriggs M.K. CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. J Exp Med 1993, 178(2):669-674.
111. Caux C., Massacrier C., Vanbervliet B., Dubois B., van Kooten C., Durand I., et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med 1994, 180(4):1263-1272.
112. Yellin M.J., D'Agati V., Parkinson G., Han A.S., Szema A., Baum D., et al. Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides. Arthritis Rheum 1997, 40(1):124-134.
113. Kuroiwa T., Schlimgen R., Illei G.G., McInnes I.B., Boumpas D.T. Distinct T cell/renal tubular epithelial cell interactions define differential chemokine production: implications for tubulointerstitial injury in chronic glomerulonephritides. J Immunol 2000, 164(6):3323-3329.
114. van Kooten C., Gerritsma J.S., Paape M.E., van Es L.A., Banchereau J., Daha M.R. Possible role for CD40-CD40L in the regulation of interstitial infiltration in the kidney. Kidney Int 1997, 51(3):711-721.
115. Uhm W.S., Na K., Song G.W., Jung S.S., Lee T., Park M.H., et al. Cytokine balance in kidney tissue from lupus nephritis patients. Rheumatology (Oxford) 2003, 42(8):935-938.
116. Calvani N., Richards H.B., Tucci M., Pannarale G., Silvestris F. Up-regulation of IL-18 and predominance of a Th1 immune response is a hallmark of lupus nephritis. Clin Exp Immunol 2004, 138(1):171-178.
117. Masutani K., Akahoshi M., Tsuruya K., Tokumoto M., Ninomiya T., Kohsaka T., et al. Predominance of Th1 immune response in diffuse proliferative lupus nephritis. Arthritis Rheum 2001, 44(9):2097-2106.
118. Tucci M., Lombardi L., Richards H.B., Dammacco F., Silvestris F. Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritis. Clin Exp Immunol 2008, 154(2):247-254.
119. Chan R.W., Tam L.S., Li E.K., Lai F.M., Chow K.M., Lai K.B., et al. Inflammatory cytokine gene expression in the urinary sediment of patients with lupus nephritis. Arthritis Rheum 2003, 48(5):1326-1331.
120. Akahoshi M., Nakashima H., Tanaka Y., Kohsaka T., Nagano S., Ohgami E., et al. Th1/Th2 balance of peripheral T helper cells in systemic lupus erythematosus. Arthritis Rheum 1999, 42(8):1644-1648.
121. Jacob C.O., van der Meide P.H., McDevitt H.O. In vivo treatment of (NZB x NZW) F1 lupus-like nephritis with monoclonal antibody to gamma interferon. J Exp Med 1987, 166(3):798-803.
122. Peng S.L., Moslehi J., Craft J. Roles of interferon-gamma and interleukin-4 in murine lupus. J Clin Invest 1997, 99(8):1936-1946.
123. Balomenos D., Rumold R., Theoilopoulos A.N. Interferonγ is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J Clin Invest 1998, 101(2):364-371.
124. Bossù P., Neumann D., Del Giudice E., Ciaramella A., Gloaguen I., Fantuzzi G., et al. IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease. Proc Natl Acad Sci USA 2003, 100(24):14181-14816.
125. Kaliyaperumal A., Mohan C., Wu W., Datta S.K. Nucleosomal peptide epitopes for nephritis-inducing T helper cells of murine lupus. J Exp Med 1996, 183(6):2459-2469.
126. Khalil M., Inaba K., Steinman R., Ravetch J., Diamond B. T cell studies in a peptide-induced model of systemic lupus erythematosus. J Immunol 2001, 166(3):1667-1674.
127. Teramoto K., Negoro N., Kitamoto K., Iwai T., Iwao H., Okamura M., et al. Microarray analysis of glomerular gene expression in murine lupus nephritis. J Pharmacol Sci 2008, 106(1):56-67.
128. Nakajima A., Hirose S., Yagita H., Okumura K. Roles of IL-4 and IL-12 in the development of lupus in NZB/W F1 mice. J Immunol 1997, 158(3):1466-1472.
129. Rüger B.M., Erb K.J., He Y., Lane J.M., Davis P.F., Hasan Q. Interleukin-4 transgenic mice develop glomerulosclerosis independent of immunoglobulin deposition. Eur J Immunol 2000, 30(9):2698-2703.
130. Singh R.R. IL-4 and many roads to lupuslike autoimmunity. Clin Immunol 2003, 108(2):73-79.
131. Kurts C. Dendritic cells: Not just another cell type in the kidney, but a complex immune sentinel network. Kidney Int 2006, 70(3):412-414.
132. Woltman A.M., de Fijter J.W., Zuidwijk K., Vlug A.G., Bajema I.M., van der Kooij S.W., et al. Quantification of dendritic cell subsets in human renal tissue under normal and pathological conditions. Kidney Int 2007, 71(10):1001-1008.
133. Krüger T., Benke D., Eitner F., Lang A., Wirtz M., Hamilton-Williams E.E., et al. Identification and functional characterization of dendritic cells in the healthy murine kidney and in experimental glomerulonephritis. J Am Soc Nephrol 2004, 15(3):613-621.
134. Soos T.J., Sims T.N., Barisoni L., Lin K., Littman D.R., Dustin M.L., et al. CX(3)CR1(+) interstitial dendritic cells form a contiguous network throughout the entire kidney. Kidney Int 2006, 70(3):591-596.
135. Fiore N., Castellano G., Blasi A., Capobianco C., Loverre A., Montinaro V., et al. Immature myeloid and plasmacytoid dendritic cells infiltrate renal tubulointerstitium in patients with lupus nephritis. Mol Immunol 2008, 45(1):259-265.
136. Tucci M., Quatraro C., Lombardi L., Pellegrino C., Dammacco F., Silvestris F. Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18. Arthritis Rheum 2008, 58(1):251-262.
137. Cederblad B., Blomberg S., Vallin H., Perers A., Alm G.V., Rönnblom L. Patients with systemic lupus erythematosus have reduced numbers of circulating natural interferon-alpha- producing cells. J Autoimmun 1998, 11(5):465-470.
138. Gill M.A., Blanco P., Arce E., Pascual V., Banchereau J., Palucka A.K. Blood dendritic cells and DC-poietins in systemic lupus erythematosus. Hum Immunol 2002, 63(12):1172-1180.
139. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000, 18:767-811.
140. Farkas L., Beiske K., Lund-Johansen F., Brandtzaeg P., Jahnsen F.L. Plasmacytoid dendritic cells (natural interferon-alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 2001, 159(1):237-243.
141. Bagavant H., Deshmukh U.S., Wang H., Ly T., Fu S.M. Role for nephritogenic T cells in lupus glomerulonephritis: progression to renal failure is accompanied by T cell activation and expansion in regional lymph nodes. J Immunol 2006, 177(11):8258-8265.
142. Schiffer L., Bethunaickan R., Ramanujam M., Huang W., Schiffer M., Tao H., et al. Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis. J Immunol 2008, 180(3):1938-1947.
143. Fujinaka H., Nameta M., Kovalenko P., Matsuki A., Kato N., Nishimoto G., et al. Periglomerular accumulation of dendritic cells in rat crescentic glomerulonephritis. J Nephrol 2007, 20(3):357-363.
144. Scholz J., Lukacs-Kornek V., Engel D.R., Specht S., Kiss E., Eitner F., et al. Renal dendritic cells stimulate IL-10 production and attenuate nephrotoxic nephritis. J Am Soc Nephrol 2008, 19(3):527-537.
145. Heymann F., Meyer-Schwesinger C., Hamilton-Williams E.E., Hammerich L., Panzer U., Kaden S., et al. Kidney dendritic cell activation is required for progression of renal disease in a mouse model of glomerular injury. J Clin Invest 2009, 119(5):1286-1297.
146. Zhu J., Liu X., Xie C., Yan M., Yu Y., Sobel E.S., et al. T cell hyperactivity in lupus as a consequence of hyperstimulatory antigen-presenting cells. J Clin Invest 2005, 115(7):1869-1878.
147. Monrad S., Kaplan M.J. Dendritic cells and the immunopathogenesis of systemic lupus erythematosus. Immunol Res 2007, 37(2):135-145.
148. Kaser A., Kaser S., Kaneider N.C., Enrich B., Wiedermann C.J., Tilg H. Interleukin-18 attracts plasmacytoid dendritic cells (DC2s) and promotes Th1 induction by DC2s through IL-18 receptor expression. Blood 2004, 103(2):648-655.
149. Siegal F.P., Kadowaki N., Shodell M., Fitzgerald-Bocarsly P.A., Shah K., Ho S., et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999, 284(5421):1835-1837.
150. Banchereau J., Pascual V., Palucka A.K. Autoimmunity through cytokine-induced dendritic cell activation. Immunity 2004, 20(5):539-550.
151. Kurts C., Heath W.R., Carbone F.R., Allison J., Miller J.F., Kosaka H. Constitutive class I-restricted exogenous presentation of self antigens in vivo. J Exp Med 1996, 184(3):923-930.
152. Coates P.T., Colvin B.L., Ranganathan A., Duncan F.J., Lan Y.Y., Shufesky W.J., et al. CCR and CC chemokine expression in relation to Flt3 ligand-induced renal dendritic cell mobilization. Kidney Int 2004, 66(5):1907-1917.
153. + T cell-dendritic cell interaction. Nature 2006, 440(7086):890-895.
154. Tucci M., Calvani N., Richards H.B., Quatraro C., Silvestris F. The interplay of chemokines and dendritic cells in the pathogenesis of lupus nephritis. Ann N Y Acad Sci 2005, 1051:421-432.
155. Hooke D.H., Gee D.C., Atkins R.C. Leukocyte analysis using monoclonal antibodies in human glomerulonephritis. Kidney Int 1987, 31(4):964-972.
156. Alexopoulos E., Seron D., Hartley R.B., Cameron J.S. Lupus nephritis: correlation of interstitial cells with glomerular function. Kidney Int 1990, 37(1):100-109.
157. Kootstra C.J., Sutmuller M., Baelde H.J., de Heer E., Bruijn J.A. Association between leukocyte infiltration and development of glomerulosclerosis in experimental lupus nephritis. J Pathol 1998, 184(2):219-225.
158. Lan H.Y., Nikolic-Paterson D.J., Mu W., Atkins R.C. Local macrophage proliferation in the pathogenesis of glomerular crescent formation in rat anti-glomerular basement membrane (GBM) glomerulonephritis. Clin Exp Immunol 1997, 110(2):233-240.
159. Huang X.R., Tipping P.G., Apostolopoulos J., Oettinger C., D'Souza M., Milton G., et al. Mechanisms of T cell-induced glomerular injury in anti-glomerular basement membrane (GBM) glomerulonephritis in rats. Clin Exp Immunol 1997, 109(1):134-142.
160. Holdsworth S.R., Neale T.J., Wilson C.B. Abrogation of macrophage-dependent injury in experimental glomerulonephritis in the rabbit. Use of an antimacrophage serum. J Clin Invest 1981, 68(3):686-698.
161. Duffield J.S., Tipping P.G., Kipari T., Cailhier J.F., Clay S., Lang R., et al. Conditional ablation of macrophages halts progression of crescentic glomerulonephritis. Am J Pathol 2005, 167(5):1207-1219.
162. Ikezumi Y., Hurst L.A., Masaki T., Atkins R.C., Nikolic-Paterson D.J. Adoptive transfer studies demonstrate that macrophages can induce proteinuria and mesangial cell proliferation. Kidney Int 2003, 63(1):83-95.
163. Holdsworth S.R., Neale T.J. Macrophage-induced glomerular injury. Cell transfer studies in passive autologous antiglomerular basement membrane antibody-initiated experimental glomerulonephritis. Lab Invest 1984, 51(2):172-180.
164. Du Y., Fu Y., Mohan C. Experimental anti-GBM nephritis as an analytical tool for studying spontaneous lupus nephritis. Arch Immunol Ther Exp (Warsz) 2008, 56(1):31-40.
165. Tesch G.H., Maifert S., Schwarting A., Rollins B.J., Kelley V.R. Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas(lpr) mice. J Exp Med 1999, 190(12):1813-1824.
166. Holdsworth S.R., Tipping P.G. Leukocytes in glomerular injury. Semin Immunopathol 2007, 29(4):355-374.
167. Boyce N.W., Tipping P.G., Holdsworth S.R. Glomerular macrophages produce reactive oxygen species in experimental glomerulonephritis. Kidney Int 1989, 35(3):778-782.
168. Khan S.B., Cook H.T., Bhangal G., Smith J., Tam F.W., Pusey C.D. Antibody blockade of TNF-alpha reduces inflammation and scarring in experimental crescentic glomerulonephritis. Kidney Int 2005, 67(5):1812-1820.
169. Little M.A., Bhangal G., Smyth C.L., Nakada M.T., Cook H.T., Nourshargh S., et al. Therapeutic effect of anti-TNF alpha antibodies in an experimental model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis. J Am Soc Nephrol 2006, 17(1):160-169.
170. Timoshanko J.R., Kitching A.R., Iwakura Y., Holdsworth S.R., Tipping P.G. Leukocyte derived interleukin-1beta interacts with renal interleukin-1 receptor I to promote renal tumor necrosis factor and glomerular injury in murine crescentic glomerulonephritis. Am J Pathol 2004, 164(6):1967-1977.
171. Timoshanko J.R., Kitching A.R., Iwakura Y., Holdsworth S.R., Tipping P.G. Contributions of IL-1beta and IL-1alpha to crescentic glomerulonephritis in mice. J Am Soc Nephrol 2004, 15(4):910-918.
172. Timoshanko J.R., Sedgwick J.D., Holdsworth S.R., Tipping P.G. Intrinsic renal cells are the major source of tumor necrosis factor contributing to renal injury in murine crescentic glomerulonephritis. J Am Soc Nephrol 2003, 14(7):1785-1793.
173. Entani C., Izumino K., Takata M., Futamura A., Nakagawa Y., Inoue H., et al. Expression of platelet-derived growth factor in lupus nephritis in MRL/MpJ-lpr/lpr mice. Nephron 1997, 77(1):100-104.
174. Troyer D.A., Chandrasekar B., Barnes J.L., Fernandes G. Calorie restriction decreases platelet-derived growth factor (PDGF)-A and thrombin receptor mRNA expression in autoimmune murine lupus nephritis. Clin Exp Immunol 1997, 108(1):58-62.
175. Sadanaga A., Nakashima H., Masutani K., Miyake K., Shimizu S., Igawa T., et al. Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice. Arthritis Rheum 2005, 52(12):3987-3996.
176. Saxena V., Lienesch D.W., Zhou M., Bommireddy R., Azhar M., Doetschman T., et al. Dual roles of immunoregulatory cytokine TGF-beta in the pathogenesis of autoimmunity-mediated organ damage. J Immunol 2008, 180(3):1903-1912.
177. Cochrane C.G., Unanue E.R., Dixon F.J. A role of polymorphonuclear leukocytes and complement in nephrotoxic nephritis. J Exp Med 1965, 122(1):99-116.
178. Naish P.F., Thomson N.M., Simpson I.J., Peters D.K. The role of polymorphonuclear leucocytes in the autologous phase of nephrotoxic nephritis. Clin Exp Immunol 1975, 22(1):102-111.
179. Henson P.M. Pathologic mechanisms in neutrophil-mediated injury. Am J Pathol 1972, 68(3):593-612.
180. Camussi G., Cappio F.C., Messina M., Coppo R., Stratta P., Vercellone A. The polymorphonuclear neutrophil (PMN) immunohistological technique: detection of immune complexes bound to the PMN membrane in acute poststreptococcal and lupus nephritis. Clin Nephrol 1980, 14(6):280-287.
181. Oda T., Hotta O., Taguma Y., Kitamura H., Sudo K., Horigome I., et al. Involvement of neutrophil elastase in crescentic glomerulonephritis. Hum Pathol 1997, 28(6):720-728.
182. Scapini P., Carletto A., Nardelli B., Calzetti F., Roschke V., Merigo F., et al. Proinflammatory mediators elicit secretion of the intracellular B-lymphocyte stimulator pool (BLyS) that is stored in activated neutrophils: implications for inflammatory diseases. Blood 2005, 105(2):830-837.
183. van Gisbergen K.P., Sanchez-Hernandez M., Geijtenbeek T.B., van Kooyk Y. Neutrophils mediate immune modulation of dendritic cells through glycosylation-dependent interactions between Mac-1 and DC-SIGN. J Exp Med 2005, 201(8):1281-1292.
184. Johnson R.J., Couser W.G., Alpers C.E., Vissers M., Schulze M., Klebanoff S.J. The human neutrophil serine proteinases, elastase and cathepsin G, can mediate glomerular injury in vivo. J Exp Med 1988, 168(3):1169-1174.
185. Johnson R.J., Lovett D., Lehrer R.I., Couser W.G., Klebanoff S.J. Role of oxidants and proteases in glomerular injury. Kidney Int 1994, 45(2):352-359.
186. Suzuki S., Gejyo F., Kuroda T., Kazama J.J., Imai N., Kimura H., et al. Effects of a novel elastase inhibitor, ONO-5046, on nephrotoxic serum nephritis in rats. Kidney Int 1998, 53(5):1201-1208.
187. Hinze C.H., Suzuki M., Klein-Gitelman M., Passo M.H., Olson J., Singer N.G., et al. Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity. Arthritis Rheum 2009, 60(9):2772-2781.
188. Suzuki M., Wiers K.M., Klein-Gitelman M.S., Haines K.A., Olson J., Onel K.B., et al. Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis. Pediatr Nephrol 2008, 23(3):403-412.
189. Schwartz N., Michaelson J.S., Putterman C. Lipocalin-2, TWEAK, and other cytokines as urinary biomarkers for lupus nephritis. Ann N Y Acad Sci 2007, 1109:265-274.
190. Ka S.M., Rifai A., Chen J.H., Cheng C.W., Shui H.A., Lee H.S., et al. Glomerular crescent-related biomarkers in a murine model of chronic graft versus host disease. Nephrol Dial Transplant 2006, 21(2):288-298.
191. Tipping P.G., Timoshanko J. Contributions of intrinsic renal cells to crescentic glomerulonephritis. Nephron Exp Nephrol 2005, 101(4):e173-178.
192. Timoshanko J.R., Tipping P.G. Resident kidney cells and their involvement in glomerulonephritis. Curr Drug Targets Inflamm Allergy 2005, 4(3):353-362.
193. Li S., Kurts C., Kontgen F., Holdsworth S.R., Tipping P.G. Major histocompatibility complex class II expression by intrinsic renal cells is required for crescentic glomerulonephritis. J Exp Med 1998, 188(3):597-602.
194. Molano A., Lakhani P., Aran A., Burkly L.C., Michaelson J.S., Putterman C. TWEAK stimulation of kidney resident cells in the pathogenesis of graft versus host induced lupus nephritis. Immunol Lett 2009, 125(2):119-128.
195. Gómez-Guerrero C., Hernández-Vargas P., López-Franco O., Ortiz-Muñoz G., Egido J. Mesangial cells and glomerular inflammation: from the pathogenesis to novel therapeutic approaches. Curr Drug Targets Inflamm Allergy 2005, 4(3):341-351.
196. Radeke H.H., Resch K. The inflammatory function of renal glomerular mesangial cells and their interaction with the cellular immune system. Clin Investig 1992, 70(9):825-842.
197. Martin M., Schwinzer R., Schellekens H., Resch K. Glomerular mesangial cells in local inflammation. Induction of the expression of MHC class II antigens by IFN-gamma. J Immunol 1989, 142(6):1887-1894.
198. Brennan D.C., Jevnikar A.M., Takei F., Reubin-Kelley V.E. Mesangial cell accessory functions: mediation by intercellular adhesion molecule-1. Kidney Int 1990, 38(6):1039-1046.
199. Baudeau C., Delarue F., Hé C.J., Nguyen G., Adida C., Peraldi M.N., et al. Induction of MHC class II molecules HLA-DR, -DP and -DQ and ICAM 1 in human podocytes by gamma-interferon. Exp Nephrol 1994, 2(5):306-312.
200. Coers W., Brouwer E., Vos J.T., Chand A., Huitema S., Heeringa P., et al. Podocyte expression of MHC class I and II and intercellular adhesion molecule-1 (ICAM-1) in experimental pauci-immune crescentic glomerulonephritis. Clin Exp Immunol 1994, 98(2):279-286.
201. Reiser J., von Gersdorff G., Loos M., Oh J., Asanuma K., Giardino L., et al. Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest 2004, 113(10):1390-1397.
202. Bariéty J., Bruneval P., Meyrier A., Mandet C., Hill G., Jacquot C. Podocyte involvement in human immune crescentic glomerulonephritis. Kidney Int 2005, 68(3):1109-1119.
203. Thorner P.S., Ho M., Eremina V., Sado Y., Quaggin S. Podocytes contribute to the formation of glomerular crescents. J Am Soc Nephrol 2008, 19(3):495-502.
204. Moeller M.J., Soofi A., Hartmann I., Le Hir M., Wiggins R., Kriz W., et al. Podocytes populate cellular crescents in a murine model of inflammatory glomerulonephritis. J Am Soc Nephrol 2004, 15(1):61-67.
205. Yokoyama H., Zheng X., Strom T.B., Kelley V.R. B7(+)-transfectant tubular epithelial cells induce T cell anergy, ignorance or proliferation. Kidney Int 1994, 45(4):1105-1112.
206. Ishikura H., Takahashi C., Kanagawa K., Hirata H., Imai K., Yoshiki T. Cytokine regulation of ICAM-1 expression on human renal tubular epithelial cells in vitro. Transplantation 1991, 51(6):1272-1275.
207. Laxmanan S., Datta D., Geehan C., Briscoe D.M., Pal S. CD40: a mediator of pro- and anti-inflammatory signals in renal tubular epithelial cells. J Am Soc Nephrol 2005, 16(9):2714-2723.
208. Niemann-Masanek U., Mueller A., Yard B.A., Waldherr R., van der Woude F.J. B7-1 (CD80) and B7-2 (CD 86) expression in human tubular epithelial cells in vivo and in vitro. Nephron 2002, 92(3):542-556.
209. Chen Y., Yang C., Xie Z., Zou L., Ruan Z., Zhang X., et al. Expression of the novel co-stimulatory molecule B7-H4 by renal tubular epithelial cells. Kidney Int 2006, 70(12):2092-2099.
210. Postlethwaite A.E., Shigemitsu H., Kanangat S. Cellular origins of fibroblasts: possible implications for organ fibrosis in systemic sclerosis. Curr Opin Rheumatol 2004, 16(6):733-738.
211. Zeisberg E.M., Potenta S.E., Sugimoto H., Zeisberg M., Kalluri R. Fibroblasts in Kidney Fibrosis Emerge via Endothelialto- Mesenchymal Transition. J Am Soc Nephrol 2008, 19(12):2282-2287.
212. Ka S.M., Cheng C.W., Shui H.A., Wu W.M., Chang D.M., Lin Y.C., et al. Mesangial cells of lupus-prone mice are sensitive to chemokine production. Arthritis Res Ther 2007, 9(4):R67.
213. Reilly C.M., Oates J.C., Cook J.A., Morrow J.D., Halushka P.V., Gilkeson G.S. Inhibition of mesangial cell nitric oxide in MRL/lpr mice by prostaglandin J2 and proliferator activation receptor-gamma agonists. J Immunol 2000, 164(3):1498-1504.
214. Reilly C.M., Oates J.C., Sudian J., Crosby M.B., Halushka P.V., Gilkeson G.S. Prostaglandin J(2) inhibition of mesangial cell iNOS expression. Clin Immunol 2001, 98(3):337-345.
215. Deocharan B., Qing X., Lichauco J., Putterman C. Alpha-actinin is a cross-reactive renal target for pathogenic anti-DNAnantibodies. J Immunol 2002, 168(6):3072-3078.
216. Zhao Z., Deocharan B., Scherer P.E., Ozelius L.J., Putterman C. Differential binding of cross-reactive anti-DNA antibodies to mesangial cells: the role of alpha-actinin. J Immunol 2006, 176(12):7704-7714.
217. Cancro M.P., D'Cruz D.P., Khamashta M.A. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest 2009, 119(5):1066-1073.
218. Nalbandian A., Crispín J.C., Tsokos G.C. Interleukin-17 and systemic lupus erythematosus: current concepts. Clin Exp Immunol 2009, 157(2):209-215.
219. Crispín J.C., Oukka M., Bayliss G., Cohen R.A., Van Beek C.A., Stillman I.E., et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol 2008, 181(12):8761-8766.
220. Kang H.K., Liu M., Datta S.K. Low-dose peptide tolerance therapy of lupus generates plasmacytoid dendritic cells that cause expansion of autoantigen-specific regulatory T cells and contraction of inflammatory Th17 cells. J Immunol 2007, 178(12):7849-7858.
221. Jacob N., Yang H., Pricop L., Liu Y., Gao X., Zheng S.G., et al. Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand Mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway. J Immunol 2009, 182(4):2532-2541.
222. Bennett L., Palucka A.K., Arce E., Cantrell V., Borvak J., Banchereau J., et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003, 197(6):711-723.
223. Baechler E.C., Batliwalla F.M., Karypis G., Gaffney P.M., Ortmann W.A., Espe K.J., et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003, 100(5):2610-2615.
224. Kirou K.A., Lee C., George S., Louca K., Papagiannis I.G., Peterson M.G., et al. Coordinate overexpression of interferon-alpha induced genes in systemic lupus erythematosus. Arthritis Rheum 2004, 50(12):3958-3967.
225. Mathian A., Weinberg A., Gallegos M., Banchereau J., Koutouzov S. IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black × New Zealand White) F1 but not in BALB/c mice. J Immunol 2005, 174(5):2499-2506.
226. Hasegawa K., Hayashi T., Maeda K. Promotion of lupus in NZB x NZWF1 mice by plasmids encoding interferon (IFN)-gamma but not by those encoding interleukin (IL)-4. J Comp Pathol 2002, 127(1):1-6.
227. Sergiescu D., Cerutti I., Efthymiou E., Kahan A., Chany C. Adverse effects of interferon treatment on the life span of NZB mice. Biomedicine 1979, 31(2):48-51.
228. Fairhurst A.M., Mathian A., Connolly J.E., Wang A., Gray H.F., George T.A., et al. Systemic IFNα drives kidney nephritis in B6. Sle123 mice. Eur J Immunol 2008, 38(7):1948-1960.
229. Schwarting A., Paul K., Tschirner S., Menke J., Hansen T., Brenner W., et al. Interferon-beta: a therapeutic for autoimmune lupus in MRL-Faslpr mice. J Am Soc Nephrol 2005, 16(11):3264-3272.
230. Santiago-Raber M.L., Baccala R., Haraldsson K.M., Choubey D., Stewart T.A., Kono D.H., et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003, 197(6):777-788.
231. Haas C., Ryffel B., Le Hir M. IFN-gamma receptor deletion prevents autoantibody production and glomerulonephritis in lupus-prone (NZB x NZW) F1 mice. J Immunol 1998, 160(8):3713-3718.
232. Nacionales D.C., Kelly-Scumpia K.M., Lee P.Y., Weinstein J.S., Lyons R., Sobel E., et al. Deficiency of the type I interferon receptor protects mice from experimental lupus. Arthritis Rheum 2007, 56(11):3770-3783.
233. Hron J.D., Peng S.L. Type I IFN protects against murine lupus. J Immunol 2004, 173(3):2134-2142.
234. Fairhurst A.M., Xie C., Fu Y.Y., Wang A., Boudreaux C.D., Zhou X.J., et al. Type I interferons produced by resident renal cells may promote end-organ disease in autoantibody-mediated glomerulonephritis. J Immunol 2009, in press.
235. Grande J.P. Mechanisms of progression of renal damage in lupus nephritis: Pathogenesis of renal scarring. Lupus 1998, 7(9):604-610.
236. Border W.A., Ruoslahti E. Transforming growth factor beta in disease: the dark side of tissue repair. J Clin Invest 1992, 90(1):1-7.
237. Nakamura T., Ebihara I., Shirato I., Tomino Y., Koide H. Increased steady-state levels of mRNA coding for extracellular matrix components in kidneys of NZB/W F1 mice. Am J Pathol 1991, 139(2):437-450.
238. Nakamura T., Ebihara I., Nagaoka I., Osada S., Tomino Y., Koide H. Effect of methylprednisolone on transforming growth factor-beta, insulin-like growth factor-I, and basic fibroblast growth factor gene expression in the kidneys of NZB/W F1 mice. Ren Physiol Biochem 1993, 16(3):105-116.
239. Taniguchi Y., Yorioka N., Masaki T., Yamashita K., Ito T., Ueda H., et al. Role of transforming growth factor-beta 1 in glomerulonephritis. J Int Med Res 1997, 25(2):71-80.
240. S.M. Ka, X.R. Huang, H.Y. Lan, P.Y. Tsai, S.M. Yang, H.A. Shui, et al., Smad7 gene therapya meliorates an autoimmune crescentic glomerulonephritis in mice. J Am Soc Nephrol 18 (6), 1777-1788.
241. Voronov E., Dayan M., Zinger H., Gayvoronsky L., Lin J.P., Iwakura Y., et al. IL-1 beta-deficient mice are resistant to induction of experimental SLE. Eur Cytokine Netw 2006, 17(2):109-116.
242. Richards H.B., Satoh M., Shaw M., Libert C., Poli V., Reeves W.H. Interleukin 6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus. J Exp Med 1998, 188(5):985-990.
243. Yin Z., Bahtiyar G., Zhang N., Liu L., Zhu P., Robert M.E., et al. IL-10 regulates murine lupus. J Immunol 2000, 169(4):2148-2155.
244. Kontoyiannis D., Kollias G. Accelerated autoimmunity and lupus nephritis in NZB mice with an engineered heterozygous deficiency in tumor necrosis factor. Eur J Immunol 2000, 30(7):2038-2047.
245. Schorlemmer H.U., Kanzy E.J., Langner K.D., Kurrle R. Immunoregulation of SLE-like disease by the IL-1 receptor: disease modifying activity on BDF1 hybrid mice and MRL autoimmune mice. Agents Actions 1993, 39:C117-120.
246. Ishida H., Muchamuel T., Sakaguchi S., Andrade S., Menon S., Howard M. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 1994, 179(1):305-310.
247. McHale J.F., Harari O.A., Marshall D., Haskard D.O. TNF-alpha and IL-1 sequentially induce endothelial ICAM-1 and VCAM-1 expression in MRL/lpr lupus-prone mice. J Immunol 1999, 163(7):3993-4000.
248. Zoja C., Liu X.H., Donadelli R., Abbate M., Testa D., Corna D., et al. Renal expression of monocyte chemoattractant protein-1 in lupus autoimmune mice. J Am Soc Nephrol 1997, 8(5):720-729.
249. Pérez de Lema G., Maier H., Nieto E., Vielhauer V., Luckow B., Mampaso F., et al. Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis. J Am Soc Nephrol 2001, 12(7):1369-1382.
250. Marks S.D., Williams S.J., Tullus K., Sebire N.J. Glomerular expression of monocyte chemoattractant protein-1 is predictive of poor renal prognosis in pediatric lupus nephritis. Nephrol Dial Transplant 2008, 23(11):3521-3526.
251. Chan R.W., Lai F.M., Li E.K., Tam L.S., Chow K.M., Lai K.B., et al. Intrarenal cytokine gene expression in lupus nephritis. Ann Rheum Dis 2007, 66(7):886-892.
252. Noris M., Bernasconi S., Casiraghi F., Sozzani S., Gotti E., Remuzzi G., et al. Monocyte chemoattractant protein-1 is excreted in excessive amounts in the urine of patients with lupus nephritis. Lab Invest 1995, 73(6):804-809.
253. Wada T., Yokoyama H., Su S.B., Mukaida N., Iwano M., Dohi K., et al. Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. Kidney Int 1996, 49(3):761-767.
254. Lu B., Rutledge B.J., Gu L., Fiorillo J., Lukacs N.W., Kunkel S.L., et al. Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J Exp Med 1998, 187(4):601-608.
255. Hasegawa H., Kohno M., Sasaki M., Inoue A., Ito M.R., Terada M., et al. Antagonist of monocyte chemoattractant protein 1 ameliorates the initiation and progression of lupus nephritis and renal vasculitis in MRL/lpr mice. Arthritis Rheum 2003, 48(9):2555-2566.
256. Shimizu S., Nakashima H., Masutani K., Inoue Y., Miyake K., Akahoshi M., et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates nephritis in MRL/lpr mice. Rheumatology (Oxford) 2004, 43(9):1121-1128.
257. Shimizu S., Nakashima H., Karube K., Ohshima K., Egashira K. Monocyte chemoattractant protein-1 activates a regional Th1 immunoresponse in nephritis of MRL/lpr mice. Clin Exp Rheumatol 2005, 23(2):239-242.
258. Anders H.J., Frink.M., Linde Y., Banas B., Wörnle M., Cohen C.D., et al. CC chemokine ligand 5/RANTES chemokine antagonists aggravate glomerulonephritis despite reduction of glomerular leukocyte infiltration. J Immunol 2003, 170(11):5658-5666.
259. Lloyd C.M., Minto A.W., Dorf M.E., Proudfoot A., Wells T.N., Salant D.J., et al. RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J Exp Med 1997, 185(7):1371-1380.
260. Anders H.J., Belemezova E., Eis V., Segerer S., Vielhauer V., Perez de Lema G., et al. Late onset of treatment with a chemokine receptor CCR1 antagonist prevents progression of lupus nephritis in MRL-Fas(lpr) mice. J Am Soc Nephrol 2004, 15(6):1504-1513.
261. Chong B.F., Mohan C. Targeting the CXCR4/CXCL12 axis in systemic lupus erythematosus. Expert Opin Ther Targets 2009, 13(10):1147-1153.
262. Wang A., Fairhurst A.M., Tus K., Subramanian S., Liu Y., Lin F., et al. CXCR4/CXCL12 hyperexpression plays a pivotal role in the pathogenesis of lupus. J Immunol 2009, 182(7):4448-4458.
263. Balabanian K., Couderc J., Bouchet-Delbos L., Amara A., Berrebi D., Foussat A., et al. Role of the chemokine stromal cell-derived factor 1 in autoantibody production and nephritis in murine lupus. J Immunol 2003, 170(6):3392-3400.
264. Panzer U., Steinmetz O.M., Paust H.J., Meyer-Schwesinger C., Peters A., Turner J.E., et al. Chemokine receptor CXCR3 mediates T cell recruitment and tissue injury in nephrotoxic nephritis in mice. J Am Soc Nephrol 2007, 18(7):2071-2084.
265. Steinmetz O.M., Turner J.E., Paust H.J., Lindner M., Peters A., Heiss K., et al. CXCR3 Mediates Renal Th1 and Th17 Immune Response in Murine Lupus Nephritis. J Immunol 2009, 1863(7):4693-4704.
266. Mohan C., Morel L., Yang P., Watanabe H., Croker B., Gilkeson G., Wakeland E.K. Genetic dissection of lupus pathogenesis: a recipe for nephrophilic autoantibodies. J Clin Invest 1999, 103(12):1685-1695.
267. Liu K., Li Q.Z., Yu Y., Liang C., Subramanian S., Zeng Z., et al. Sle3 and Sle5 can independently couple with Sle1 to mediate severe lupus nephritis. Genes Immun 2007, 8(8):634-645.
268. Liu K., Li Q.Z., Delgado-Vega A.M., Abelson A.K., Sánchez E., Kelly J.A., et al. Kallikrein genes are associated with lupus and glomerular basement membrane-specific antibody-induced nephritis in mice and humans. J Clin Invest 2009, 119(4):911-923.
269. Li Q.Z., Zhou J., Yang R., Yan M., Ye Q., Liu K., et al. The lupus-susceptibility gene kallikrein downmodulates antibody-mediated glomerulonephritis. Genes Immun 2009, 10(5):503-508.
270. Chao J., Zhang J.J., Lin K.F., Chao L. Adenovirus-mediated kallikrein gene delivery reverses salt-induced renal injury in Dahl salt-sensitive rats. Kidney Int 1998, 54(4):1250-1260.
271. Bledsoe G., Crickman S., Mao J., Xia C.F., Murakami H., Chao L., et al. Kallikrein/kinin protects against gentamicin-induced nephrotoxicity by inhibition of inflammation and apoptosis. Nephrol Dial Transplant 2006, 21(3):624-633.
272. Schanstra J.P., Neau E., Drogoz P., Arevalo Gomez M.A., Lopez Novoa J.M., Calise D., et al. In vivo bradykinin B2 receptor activation reduces renal fibrosis. J Clin Invest 2002, 110(3):371-379.
273. Kakoki M., Takahashi N., Jennette J.C., Smithies O. Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B2 receptor. Proc Natl Acad Sci USA 2004, 101(36):13302-133305.
274. Chao J., Bledsoe G., Yin H., Chao L. The tissue kallikrein-kinin system protects against cardiovascular and renal diseases and ischemic stroke independently of blood pressure reduction. Biol Chem 2006, 387(6):665-675.
275. Furusu A., Miyazaki M., Abe K., Tsukasaki S., Shioshita K., Sasaki O., et al. Expression of endothelial and inducible nitric oxide synthase in human glomerulonephritis. Kidney Int 1998, 53(6):1760-1768.
276. Weinberg J.B., Granger D.L., Pisetsky D.S., Seldin M.F., Misukonis M.A., Mason S.N., et al. The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered NG-monomethyl-L-arginine. J Exp Med 1994, 179(2):651-660.
277. Reilly C.M., Farrelly L.W., Viti D., Redmond S.T., Hutchison F., Ruiz P., et al. Modulation of renal disease in MRL/lpr mice by pharmacologic inhibition of inducible nitric oxide synthase. Kidney Int 2002, 61(3):839-846.
278. Yasui K., Baba A. Therapeutic potential of superoxide dismutase (SOD) for resolution of inflammation. Inflamm Res 2006, 55(9):359-363.
279. Wu T., Fu Y., Brekken D., Yan M., Zhou X.J., Vanarsa K., et al. Urine proteome scans uncover total urinary protease, prostaglandin D synthase, serum amyloid P, and superoxide dismutase as potential markers of lupus nephritis. J Immunol 2010, 184(4):2183-2193.
280. Wang J.S., Ger L.P., Tseng H.H. Expression of glomerular antioxidant enzymes in human glomerulonephritis. Nephron 1997, 76(1):32-38.
281. Taysi S., Gul M., Sari R.A., Akcay F., Bakan N. Serum oxidant/antioxidant status of patients with systemic lupus erythematosus. Clin Chem Lab Med 2002, 40(7):684-688.
282. Bloom R.D., Florquin S., Singer G.G., Brennan D.C., Kelley V.R. Colony stimulating factor-1 in the induction of lupus nephritis. Kidney Int 1993, 143(5):1000-1009.
283. Isbel N.M., Hill P.A., Foti R., Mu W., Hurst L.A., Stambe C., et al. Tubules are the major site of M-CSF production in experimental kidney disease: correlation with local macrophage proliferation. Kidney Int 2001, 60(2):614-625.
284. Yui M.A., Brissette W.H., Brennan D.C., Wuthrich R.P., Rubin-Kelley V.E. Increased macrophage colony-stimulating factor in neonatal and adult autoimmune MRL-lpr mice. Am J Pathol 1991, 139(2):255-261.
285. Naito T., Yokoyama H., Moore K.J., Dranoff G., Mulligan R.C., Kelley V.R. Macrophage growth factors introduced into the kidney initiate renal injury. Mol Med 1996, 2(3):297-312.
286. Lenda D.M., Stanley E.R., Kelley V.R. Negative role of colonystimulating factor-1 in macrophage, T cell, and B cell mediated autoimmune disease in MRL-Fas(lpr) mice. J Immunol 2004, 173(7):4744-4754.
287. Lan H.Y., Yang N., Nikolic-Paterson D.J., Yu X.Q., Mu W., Isbel N.M., et al. Expression of macrophage migration inhibitory factor in human glomerulonephritis. Kidney Int 2000, 57(2):499-509.
288. Lan H.Y., Mu W., Yang N., Meinhardt A., Nikolic-Paterson D.J., Ng Y.Y., et al. De novo renal expression of macrophage migration inhibitory factor during the development of rat crescentic glomerulonephritis. Am J Pathol 1996, 149(4):1119-1127.
289. Otukesh H., Chalian M., Hoseini R., Chalian H., Hooman N., Bedayat A., et al. Urine macrophage migration inhibitory factor in pediatric systemic lupus erythematosus. Clin Rheumatol 2007, 26(12):2105-2107.
290. Hoi A.Y., Hickey M.J., Hall P., Yamana J., O'Sullivan K.M., Santos L.L., et al. Macrophage migration inhibitory factor deficiency attenuates macrophage recruitment, glomerulonephritis, and lethality in MRL/lpr mice. J Immunol 2006, 177(8):5687-5696.
291. Sasaki S., Nishihira J., Ishibashi T., Yamasaki Y., Obikane K., Echigoya M., et al. Transgene of MIF induces podocyte injury and progressive mesangial sclerosis in the mouse kidney. Kidney Int 2004, 65(2):469-481.
292. Yang N., Nikolic-Patersonm D.J., Ng Y.Y., Mu W., Metz C., Bacher M., et al. Reversal of established rat crescentic glomerulonephritis by blockade of macrophage migration inhibitory factor (MIF): potential role of MIF in regulating glucocorticoid production. Mol Med 1998, 4(6):413-424.
293. Lan H.Y., Bacher M., Yang N., Mu W., Nikolic-Paterson D.J., Metz C., et al. The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat. J Exp Med 1997, 185(8):1455-1465.